Autoimmune Diseases

Oct 4, 2024 | academic.oup.com | Autoimmune Diseases |Institut Imagine |Université Paris-Cité

Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.

Apr 23, 2024 | taiwannews.com.tw | Autoimmune Diseases

Report Ocean is a comprehensive analysis of the “Saudi Arabia Pharmerging Market” market that includes both qualitative and quantitative data. The report covers various regions and provides insights into major industry changes, challenges faced by businesses and competitors, and potential new opportunities in the market.

Apr 19, 2024 | taiwannews.com.tw | Autoimmune Diseases

Report Ocean recently added a research report on “Biosimilar Monoclonal Antibody Market”. The report includes an extensive analysis of the market’s characteristics, COVID-19 impact, size and growth, segmentation, regional and country breakdowns, competitive environment, market shares, trends, and strategies. In addition, it traces the development of the market over time and projects regional market growth. It compares the market to other markets and situates it in relation to the larger market.

Nov 9, 2023 | menafn.com | Autoimmune Diseases

(MENAFN- Alliance News) The most recent publication by Report Ocean emphasize s the potential growth of "Saudi Arabia Pharmerging Market" from 2023 to 2032. The report entails comprehensive research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast . It offers a purposeful portrayal of the sector through meticulous research practices, amalgamating data from various sources to provide an overview of market size and analysis.

Aug 23, 2023 | arthritis-research.biomedcentral.com | Autoimmune Diseases

We prospectively enrolled 13 pSS patients who fulfilled the classification criteria of the 2002 American European Consensus Group from Peking Union Medical College Hospital (PUMCH) (Supplementary Table S1). Patients received 25 mg twice daily IGU due to clinical manifestations and did not receive glucocorticoids and immunosuppressants.